Publicaciones en las que colabora con Alfonso Calvo González (20)

2024

  1. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation

    Molecular Cancer, Vol. 23, Núm. 1

2022

  1. Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 1

2021

  1. Molecular biomarkers in early stage lung cancer

    Translational Lung Cancer Research, Vol. 10, Núm. 2, pp. 1165-1185

  2. SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation

    Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3

2020

  1. Id1 and pd-1 combined blockade impairs tumor growth and survival of KRAS-mutant lung cancer by stimulating PD-l1 expression and tumor infiltrating CD8+ T cells

    Cancers, Vol. 12, Núm. 11, pp. 1-22

  2. Short-term starvation reduces IGF-1 levels to sensitize lung tumors to PD-1 immune checkpoint blockade

    Nature cancer, Vol. 1, Núm. 1, pp. 75-85

2019

  1. Identification of a novel synthetic lethal vulnerability in non-small cell lung cancer by co-targeting TMPRSS4 and DDR1

    Scientific Reports, Vol. 9, Núm. 1

  2. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  3. Targeting of TMPRSS4 sensitizes lung cancer cells to chemotherapy by impairing the proliferation machinery

    Cancer Letters, Vol. 453, pp. 21-33

  4. Tmprss4: A novel tumor prognostic indicator for the stratification of stage ia tumors and a liquid biopsy biomarker for nsclc patients

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  5. YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib

    American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Epigenetic alterations leading to TMPRSS4 promoter hypomethylation and protein overexpression predict poor prognosis in squamous lung cancer patients

    Oncotarget, Vol. 7, Núm. 16, pp. 22752-22769

2014

  1. New syngeneic inflammatory-related lung cancer metastatic model harboring double KRAS/WWOX alterations

    International Journal of Cancer, Vol. 135, Núm. 11, pp. 2516-2527

2011

  1. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance

    Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166

  2. Overexpression of TMPRSS4 in non-small cell lung cancer is associated with poor prognosis in patients with squamous histology

    British Journal of Cancer, Vol. 105, Núm. 10, pp. 1608-1614

2010

  1. VEGF121b and VEGF165b are weakly angiogenic isoforms of VEGF-A

    Molecular Cancer, Vol. 9

2008

  1. Identification of Importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens

    BMC Molecular Biology, Vol. 9

2007

  1. Alternative splicing: an emerging topic in molecular and clinical oncology

    Lancet Oncology, Vol. 8, Núm. 4, pp. 349-357

2003

  1. Overexpression of adrenomedullin gene markedly inhibits proliferation of PC3 prostate cancer cells in vitro and in vivo

    Molecular and Cellular Endocrinology, Vol. 199, Núm. 1-2, pp. 179-187